Replies to post #73176 on Biotech Values

[DewDiligence]

Re: Biogenerics vs Biosimilars

I see no support whatsoever for Gottlieb’s assertion that the exclusivity period in FoB legislation has been rendered moot. The Myozyme/Lumizyme case merely means that the FAA is treating Lumizyme as a biosimilar rather than a biogeneric.